Vivosim Labs Inc 's ability to collect accounts receivable sequentially worsen to 3.64, indicating more challenging environment then in the fourth quarter 2026, but still, it is a far cry from any concerns. Vivosim Labs Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 100 days, from 88 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 609 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 0 to 4343.

What is Receivable Turnover Ratio?
What is Vivosim Labs Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VIVS Receivables Turnover Ratio	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Receivable Change	-9.37 %	6.67 %	-9.09 %	10.34 %	-33.33 %
Y / Y Revenue Change	-51.35 %	-21.57 %	8.33 %	-6.67 %	-5.13 %
Receivable Turnover Ratio (TTM)	3.64	4.16	4.58	4.41	4.58
VIVS's Total Ranking	# 4343	# 0	# 0	# 0	# 0
Accounts Receivable average collection period days	100	88	80	83	80
Seq. Receivable Change	-9.37 %	6.67 %	-6.25 %	0 %	6.67 %
Seq. Revenue Change	-55 %	53.85 %	-7.14 %	-24.32 %	-27.45 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 77
Healthcare Sector	# 610
Overall Market	# 4343

Receivable Turnover Ratio Statistics
High	Average	Low
0.08	0.04	0.01
(Jun 30 2018)		(Jun 30 2014)

VIVS Company Profile • Back to VIVS Efficiency Comparisons • Compare VIVS Receivables Turnover Ratio to its Competitors

Financial Statements
Vivosim Labs Inc 's Accounts Receivable	$ 0 Millions	Visit VIVS's Balance sheet
Vivosim Labs Inc 's Sales TTM	$ 0 Millions	Visit VIVS's Income Statement
Sources of VIVS's Revenues		Visit VIVS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
VIVS's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
VIVS's Growth Rates	VIVS's Roa	VIVS's Inventory Turnover Ratio	VIVS's Dividend Comparisons
VIVS's Profitability Ratios	VIVS's Roi	VIVS's Asset Turnover Ratio	VIVS's Dividend Growth
VIVS's Valuation Ratios	VIVS's Roe	VIVS's Financial Strength Ratios	VIVS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Radnet Inc	10.53	$ 2,268.932 Millions	$ 215.450 Millions
Kymera Therapeutics Inc	10.50	$ 105.000 Millions	$ 10.000 Millions
Irhythm Holdings Inc	10.42	$ 825.702 Millions	$ 79.250 Millions
Integrated Biopharma Inc	10.38	$ 42.568 Millions	$ 4.101 Millions
Viemed Healthcare Inc	10.36	$ 301.606 Millions	$ 29.102 Millions
Lensar Inc	10.33	$ 60.264 Millions	$ 5.836 Millions
Immucell Corporation	10.30	$ 29.777 Millions	$ 2.891 Millions
Addus Homecare Corp	10.25	$ 1,475.610 Millions	$ 143.923 Millions
Dariohealth Corp	10.23	$ 21.196 Millions	$ 2.072 Millions
Biodesix Inc	10.21	$ 102.939 Millions	$ 10.081 Millions
Kestra Medical Technologies Ltd	10.00	$ 105.939 Millions	$ 10.590 Millions
United Therapeutics Corporation	9.93	$ 3,154.500 Millions	$ 317.550 Millions
Utah Medical Products Inc	9.88	$ 35.679 Millions	$ 3.612 Millions
Biolife Solutions Inc	9.67	$ 102.718 Millions	$ 10.626 Millions
The Oncology Institute Inc	9.66	$ 587.244 Millions	$ 60.780 Millions
Sharps Technology Inc	9.65	$ 1.960 Millions	$ 0.203 Millions
Encompass Health Corporation	9.57	$ 6,206.100 Millions	$ 648.325 Millions
Septerna Inc	9.42	$ 98.882 Millions	$ 10.501 Millions
Biofrontera Inc	9.33	$ 45.956 Millions	$ 4.928 Millions
Enanta Pharmaceuticals Inc	9.29	$ 65.258 Millions	$ 7.027 Millions
The Pennant Group Inc	9.27	$ 1,101.710 Millions	$ 118.798 Millions
Crinetics Pharmaceuticals Inc	9.25	$ 42.156 Millions	$ 4.558 Millions
Neuronetics Inc	9.24	$ 154.594 Millions	$ 16.732 Millions
Myomo Inc	9.24	$ 44.242 Millions	$ 4.790 Millions
Harmony Biosciences Holdings inc	9.22	$ 960.191 Millions	$ 104.164 Millions
Bioaffinity Technologies Inc	9.18	$ 5.901 Millions	$ 0.643 Millions
Pavmed Inc	9.16	$ 0.126 Millions	$ 0.014 Millions
Clene Inc	9.16	$ 0.197 Millions	$ 0.022 Millions
Ardent Health Inc	9.16	$ 6,405.940 Millions	$ 699.363 Millions
Lexicon Pharmaceuticals Inc	9.14	$ 41.469 Millions	$ 4.535 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.